Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.55 - $31.01
Previous CloseN/A
Volume4.28M
Average Volume (3M)826.53K
Market Cap
$89.86M
Enterprise Value$191.73M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 11, 2025EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.75
Shares Outstanding15,001,353
10 Day Avg. Volume449,271
30 Day Avg. Volume826,528
Standard Deviation0.40
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.99
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-173.04
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$60.89Price Target Upside888.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyBriquilimab demonstrated clear and rapid clinical activity with initial 6-week data from the Ph I/II SPOTLIGHT study.
Market DifferentiationThere is an opportunity for briquilimab to differentiate in the chronic urticaria market by offering a competitive efficacy profile, improved safety/tolerability, and a more convenient dosing regimen relative to its competition.
Bears Say
Stock PerformanceJSPR is down ~55% following the release of preliminary data from BEACON driven by a curious dose-response relationship and a safety profile perceived to be undifferentiated from its main comparator.
---
Ownership Overview
27.62% Insiders
9.56% Mutual Funds
0.02% Other Institutional Investors
54.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $4.55 and its highest was $31.01 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $89.86M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 18 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of -$1.071 by -$0.169.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -1.25.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 15,001,353 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.24 in its last earnings report, missing expectations of -$1.071. Following the earnings report the stock price went down -4.262%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
---
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.89 (888.47% Upside)
$60.89 (888.47% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.00%
12-Months-Change
Fundamentals
Return on Equity
-71.46%
Trailing 12-Months
Asset Growth
-9.96%
Trailing 12-Months
Company Description
Jasper Therapeutics
Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
---
JSPR Stock 12 Month Forecast
Average Price Target
$60.89
▲(888.47% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering JSPR
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-33.52%
reiterated a buy rating last month
Copying Jay Olson's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -33.52% per trade.
---